S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Better Than Oil Stocks (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Better Than Oil Stocks (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Better Than Oil Stocks (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Better Than Oil Stocks (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Better Than Oil Stocks (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Better Than Oil Stocks (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Better Than Oil Stocks (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Better Than Oil Stocks (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Better Than Oil Stocks (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Better Than Oil Stocks (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Better Than Oil Stocks (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Better Than Oil Stocks (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
NASDAQ:NK

NantKwest (NK) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$3.37
$5.21
50-Day Range
$16.09
$38.70
52-Week Range
$2.52
$45.42
Volume
15.54 million shs
Average Volume
1.57 million shs
Market Capitalization
$382.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

NK stock logo

About NantKwest Stock (NASDAQ:NK)

NantKwest, Inc., a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and Nant cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer (haNK) product candidates primarily for the treatment of various cancers; and tank and t-haNK product candidates to treat solid tumors. NantKwest, Inc. has a co-development agreement with Altor BioScience, LLC to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's N-801 and/or N-803 products; collaboration with Be The Match BioTherapies for the development of cell therapy to prevent COVID-19 deaths; and strategic alliance with Immunitybio. It also has a collaboration with CBR Systems, Inc. to develop a COVID-19 treatment leveraging newborn stem cells. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.


NK Stock News Headlines

Space Nk Promo Codes
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
NantKwest Inc (IBRX) Earnings Dates & Reports
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
See More Headlines
Receive NK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NantKwest and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/11/2020
Today
2/24/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Fax
N/A
Employees
160
Year Founded
N/A

Profitability

Net Income
$-65,790,000.00
Net Margins
-76,658.58%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$40,000.00
Book Value
$1.23 per share

Miscellaneous

Free Float
N/A
Market Cap
$382.71 million
Optionable
Not Optionable
Beta
2.61
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Barry J. Simon (Age 56)
    Pres, Chief Admin. Officer & Exec. Director
    Comp: $454.44k
  • Ms. Sonja Nelson (Age 48)
    Chief Financial Officer
    Comp: $442.69k
  • Mr. Richard Gerald Adcock (Age 52)
    Chief Exec. Officer
  • Mr. Steven Yang J.D.
    VP, Gen. Counsel & Corp. Sec.
  • Dr. Jerel A. Banks Ph.D. (Age 46)
    M.D., Sr. VP Mergers and Acquisitions
  • Mr. Leonard S. Sender
    Sr. VP of Medical Affairs - Pediatric, Adolescent & Young Adult Oncology
  • Dr. Hans Georg Klingemann (Age 71)
    VP of R&D














NK Stock Analysis - Frequently Asked Questions

How were NantKwest's earnings last quarter?

NantKwest, Inc. (NASDAQ:NK) announced its quarterly earnings results on Monday, May, 11th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by $0.02. The biotechnology company earned $0.02 million during the quarter. NantKwest had a negative trailing twelve-month return on equity of 56.06% and a negative net margin of 76,658.58%.

What is Dr. Patrick Soon-Shiong's approval rating as NantKwest's CEO?

14 employees have rated NantKwest Chief Executive Officer Dr. Patrick Soon-Shiong on Glassdoor.com. Dr. Patrick Soon-Shiong has an approval rating of 55% among the company's employees. This puts Dr. Patrick Soon-Shiong in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of NantKwest own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NantKwest investors own include Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), OPKO Health (OPK), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Trevena (TRVN) and ADMA Biologics (ADMA).

When did NantKwest IPO?

(NK) raised $150 million in an IPO on Tuesday, July 28th 2015. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. BofA Merrill Lynch, Citigroup, Jefferies and Piper Jaffray served as the underwriters for the IPO and MLV & Co. was co-manager.

This page (NASDAQ:NK) was last updated on 2/24/2024 by MarketBeat.com Staff